Mylan, Upjohn deal approved unconditionally in Taiwan
MLex Summary: The proposed merger between US-based pharmaceutical company Mylan and Pfizer’s off-patent drug business, Upjohn, has been approved by the Taiwan Fair Trade Commission, the antitrust regulator said today. The...To view the full article, register now.
Already a subscriber? Click here to view full article